HETEROCYCLIC COMPOUNDS AND USES THEREOF

EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER

NUCLEIC ACID BIOMARKER AND USE THEREOF

ANTI-GPC3 ANTIBODIES, MULTISPECIFIC ANTIBODIES AND METHODS OF USE

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

METHODS FOR TREATMENT OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE

COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE

B7-H4 ANTIBODIES AND METHODS OF USE THEREOF

HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFOR

Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease

ILT3-binding agents and methods of use thereof

USE OF CANAKINUMAB

INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN

NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION

PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES

DIAGNOSIS AND TREATMENT FOR CHRONIC INFLAMMATION AND VIRUS INFECTION

Anti-ETEC adhesin protein antibodies and methods of use

ANTIBODY BINDING SPECIFICALLY TO SARS-COV-2 S PROTEIN OR ANTIGEN-BINDING FRAGMENT THEREOF, BISPECIFIC ANTIBODY, AND USES THEREOF

Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments

ANTIBODIES BINDING TO CD3

IMMUNOMODULATORY PROTEINS AND RELATED METHODS

ANTI-GARP-TGF-BETA1/PD-1 COMBINATION THERAPY

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

CMV VACCINE AND METHOD OF MAKING AND USING THE SAME

CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

CIRCULATING BIOMARKERS OF RESPONSE TO PD-1/PD-L1 BLOCKADE AND GSK-3 INHIBITION

HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3

Anti-Jagged Antibodies and Methods of Use

ANTI-PD-1 ANTIBODY AND USE THEREOF

BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMPOSITIONS AND METHODS FOR TREATING EPILEPSY

CD70 COMBINATION THERAPY

Methods of Treating Cancer Using Compositions of Antibodies and Carrier Proteins with Antibody Pretreatment

Vaccines against HPV and HPV-related diseases

Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

Method of administration and treatment

ANTIBODIES AND METHODS OF USE

METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE

ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF

INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU

Targeting intracellular target-binding determinants with intracellular antibodies

OPTIMIZED Fc VARIANTS

ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY

ANTI-OPG ANTIBODIES

Bispecific CD137-binding antibodies for T-cell activation

COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS

CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS

CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS

GALECTIN-10 ANTIBODIES

ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF

METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES

PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD)

TREATMENT OF HIDRADENITIS SUPPURATIVA

IL-7 binding proteins and their use in medical therapy

MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF

Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES

ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

RECOMBINANT PROTEIN TARGETING PD-1 AND TGFBETA

CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2

ELECTROSTATIC NANOPARTICLES AND USE THEREOF

METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY

IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY

Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20

KINASE INHIBITOR COMBINATIONS FOR CANCER TREATMENT

METHODS OF TREATING CANCER WITH A COMBINATION OF TUCATINIB AND AN ANTI-PD-1/ANTI-PD-L1 ANTIBODY

MODIFIED ONCOLYTIC VIRUS

Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody

COMPOSITIONS AND METHODS FOR DETECTING AND TREATING OVARIAN CANCER

ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF

METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibiting

CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME

ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CD19

ANTI-CD73 ANTIBODY AND USE THEREOF

AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT

METHODS OF TREATING CUTANEOUS LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS

DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES

THERAPEUTIC ANTIBODIES AND THEIR USES

METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

ANTI-CD200R1 ANTIBODIES AND METHODS OF USE THEREOF

BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3

INTRANASAL IMMUNOTHERAPT FOR THE TREATMENT OF ALZHEIMER'S DISEASE

COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION

COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY

METHODS OF USING ANTIBODIES RECOGNIZING TAU

Antibodies specific for human complement C5A receptor (C5AR)

ANTIGEN BINDING MOLECULES AND USES THEREOF

Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use

METHODS AND COMPOSITIONS FOR RESTRICTING BIODISTRIBUTION OF AAV

Antibodies that bind human C6 and uses thereof

IONIC LIQUIDS FOR DRUG DELIVERY

NATURAL KILLER CELLS WITH ENHANCED ACTIVITY

BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY

METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES

AGONISTIC CD40 ANTIBODIES

ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES

ANTIBODY MOLECULES

NOVEL ANTI-C-MPL ANTIBODY AND USE THEREOF

THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR AMYOTROPHIC LATERAL SCLEROSIS

ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D)

ANTI-PDL1 ANTIBODY FORMULATIONS

BISPECIFIC ANTIBODY AND USE THEREOF

ANTI-CTLA4 AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF

DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

Antibody Constructs for CDH19 and CD3

ANTIBODIES TARGETED TO CD147

Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

CANINE ANTIBODY VARIANTS

ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF

ANTIBODIES AGAINST STREPTOCOCCAL M PROTEIN

EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY

CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF

Glycan-Interacting Compounds and Methods of Use

USE OF NGF ANTIBODY IN CIPN PAIN

COMBINATION IMMUNOTHERAPY OF IL-15 AND CD40 AGONIST IN CANCER TREATMENT

TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS

COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF

COMBINATION CANCER THERAPY USING CHK INHIBITOR

Compositions and Methods for Targeting Cancer Stem Cells

ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY

MODIFIED NK-92 CELLS FOR TREATING CANCER

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

Compositions and Methods for Targeting Cancer Stem Cells

ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY

HER2 TARGETING AGENT

ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

METHODS AND COMPOSITIONS

USE OF IL-6 INHIBITORS FOR THE TREATMENT OF ACUTE CHEST SYNDROME IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE

TrkA antibody and application thereof

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

ANTI-CTLA-4 ANTIBODY AND USE THEREOF

Methods and compositions for modulating CAR-T activity

ANTI-LAG3 ANTIBODIES

ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT

ANTI-L1-CAM ANTIBODIES AND USES THEREOF

ANTI-CLIC1 PROTEIN ANTIBODIES AND THE DIAGNOSTIC AND THERAPEUTIC USES THEREOF

HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA

NAV1.7 BINDERS

HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY

METHODS AND TREATMENT INVOLVING EXCESS FREE LIGHT

METHODS FOR SELECTING PATIENTS FOR TREATMENT WITH AN NGF ANTAGONIST

METHOD OF TREATING OR PREVENTING LIVER CONDITIONS

ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USE

FAB HIGH MANNOSE GLYCOFORMS

Combinations of Antibodies and Bispecific Antibodies Comprising Antigen-Binding Specifically Recognizing Pseudomonas PcrV and Psl

BROADLY NEUTRALIZING ANTIBODIES TO TICK-BORNE ENCEPHALITIS AND RELATED VIRUSES

Methods and composition for neutralization of influenza

POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION

Respiratory syncytial virus (RSV) vaccine

Glycan-Interacting Compounds and Methods of Use

CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION

Antibody Compositions and Methods of Use Thereof

ANTI-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY

APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTAT

METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS

Skin Probiotics

BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Dynamic I/O virtualization system having guest memory management for mapping virtual addresses using virtualization application programming interface (API) in guest kernal

METHODS FOR DECREASING MORTALITY RISK AND IMPROVING HEALTH

Therapeutic use of mitochondria and combined mitochondrial agents

ANTI-CERAMIDE ANTIBODIES

FGF21 MIMETIC ANTIBODIES AND USES THEREOF

Tissue factor pathway inhibitor antibodies and uses thereof

HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF

ANTI-CD73 ANTIBODIES AND METHODS OF USE THEREOF

MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND CD38 AND 4-1BB, AND USES THEREOF

CD6 ANTIBODY FOR TREATMENT OF T-CELL MEDIATED DISEASES OR DISORDERS

USE OF ANTI-OX40 ANTIBODY IN TREATMENT OF TUMOR OR CANCER

Bispecific antibody binding BCMA and CD3

METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING

MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123

METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME

ALK7 Binding Proteins and Uses Thereof

BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES

HETERODIMER FC POLYPEPTIDE

BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO CANCER IMMUNOTHERAPEUTIC AGENT AND USE THEREOF

TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES

IL-8 ANTIBODIES AND METHODS OF USE THEREOF

TREATMENT OF OPHTHALMOLOGIC DISEASES

Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression

Constrained conditionally activated binding proteins

PHARMACEUTICAL COMPOSITION CONTAINING EXOSOME AND PREPARATION METHOD THEREOF

NEOANTIGENS AND METHODS OF THEIR USE

COMBINATION OF IMMUNOTHERAPY WITH LOCAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANCIES

Binding proteins 1

METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS

DOSING REGIMENS FOR USE WITH PCSK9 INHIBITORS

CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS

CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE

ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF

BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES

ANTI-CD40 ANTIBODIES AND METHODS OF USE

LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT

ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY

IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells

METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS

Anti-AXL Antagonistic Antibodies

ANTI-cMET ANTIBODY

MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF

UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR PD-LI AND USES THEREOF

Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer

METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER

METHODS FOR DETERMINING AND ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS IN TREATMENT OF CANCER

METHOD FOR TREATING SARS-COV-2 INFECTIOUS DISEASE

Neutralizing Antibodies that Bind the SARS-COV-2 S Protein

MACROCYCLIC COMPOUND AND USES THEREOF

COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF CANCER

NEOANTIGENS AND METHODS OF THEIR USE

COMBINATION PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD

Combination Therapies for Treating Cancer

Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And Trastuzumab

WARS-NEUTRALIZING ANTIBODY AND USE THEREOF

BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF

COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST

ANTIBODY TARGETING INTERLEUKIN 36R, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

MULTISPECIFIC ANTIBODIES AND USES THEREOF

TARGETED THERAPEUTIC AGENTS AND USES THEREOF

SUSTAINED ANTIBODY AND IMMUNOTHERAPEUTIC DELIVERY TO CERVICAL LYMPH NODES

Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof

ANTI-OSCAR ANTIBODY FOR PREVENTING OR TREATING OSTEOARTHRITIS

METHODS TO EXTEND HEALTH-SPAN AND TREAT AGE-RELATED DISEASES

BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES

NOVEL ANTI-NOGO-A ANTIBODIES

METHODS FOR REDUCING ALLERGIES CAUSED BY ENVIRONMENTAL ALLERGENS

METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN

ANTIBODIES TO CORONAVIRUS SPIKE PROTEIN AND METHODS OF USE THEREOF

T-cell modulatory multimeric polypeptides and methods of use thereof

Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer

COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES

COMPOSITIONS AND METHODS FOR ENHANCING T CELL PENETRATION OF TUMORS AND CANCERS

METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE

SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF

COMPOSITIONS AND METHODS FOR MUC18 TARGETING

Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38

BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF

Anti-FcRn antibody or antigen binding fragment thereof with improved stability

METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSIS

Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof

INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES

LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47

POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERAS

ANTI-CANCER INHIBITORY ANTIBODIES

BIFUNCTIONAL ANTAGONISTS OF ACTIVIN AND TUMOR NECROSIS FACTOR ALPHA AND USES THEREOF

NEUTRALIZING ANTIBODY SPECIFIC TO HUMAN DENATURED CRP, AND MEDICINE AND ANTI-INFLAMMATORY AGENT CONTAINING THE SAME

ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF

TROPHOBLAST GLYCOPROTEIN RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS

COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY

CD4+ TFH-LIKE CELLS AS A THERAPEUTIC TARGET

COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE, A PROBIOTIC, AND SEMAPHORIN

NOVEL THERAPEUTIC COMBINATIONS COMPRISING DERIVATIVES OF OXAZAPHOSPHORINES FOR THE TREATMENT OF CANCER

DASH INHIBITORS, AND USES RELATED THERETO

ANTI-CD26 ANTIBODIES AND USES THEREOF

Anti-CD46 antibodies and methods of use

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES

METHOD FOR TREATING OX40 RELATED DISEASE

Covalent Diabodies and Uses Thereof

MOLECULES BINDING PD-L1 AND USES THEREOF

Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Antibodies against TIM3 and uses thereof

Treatment for neoplastic diseases

COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF

MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER

TRABD PROTEIN, AND MONOCLONAL ANTIBODY THEREOF, AND ISOLATION, AMPLIFICATION AND USE THEREOF

POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF

ANTI-SARS-COV-2 ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS

CSF1R KINASE INHIBITOR AND USE THEREOF

ANTIBODY FRAGMENT AGAINST FAP

METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA

NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RETINAL OR CHOROIDAL DISEASE COMPRISING PLVAP AS ACTIVE INGREDIENT

ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME

BIDIRECTIONAL DUAL PROMOTER EXPRESSION VECTORS AND USES THEREOF

FOXP3S-PROMOTING MORPHOLINOS

Methods for Treating and Monitoring the Status of Cancer

ANTI-PSMA ANTIBODIES AND USES THEREOF

BCMA/TACI ANTIGEN-BINDING MOLECULES

COMBINATION THERAPY FOR ALPORT RENAL DISEASE

COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF

HUMANIZED OR CHIMERIC CD3 ANTIBODIES

BISPECIFIC ANTI LRRC15 AND CD3EPSILON ANTIBODIES

THERAPEUTIC AGENT FOR IMMUNE/INFLAMMATORY DISEASE

ANTI-LILRB1 ANTIBODY AND USES THEREOF

Leptin antibodies and method of reducing leptin

Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody

SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2

FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS FORMULATIONS WITH AGGREGATE FORMATION

Anti-MUC1 antibody-drug conjugate

ANTI-C-MET ANTIBODY DRUG CONJUGATES

THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS

ANTI-CEA ANTIBODIES

ANTI-ERBB3 ANTIBODIES

NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A